Novartis: Upside Increasingly Capped, 2026 Will Be A Transition Year (Rating Downgrade)

Novartis is a pure-play innovative medicines company with high margins and priced-in 2026 capital allocation plans. Read why ...
Morning Overview on MSN

Honda stuns space rivals by launching and landing reusable rocket in test

Honda has spent decades perfecting engines for Civics and Accords, not capsules and boosters, yet its engineers have just ...